MEDI4736
A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors
Abstract
A review and critical consideration of immunotherapeutical concepts in non-small cell lung cancer (NSCLC) is given. Nivolumab represents a promising option in various malignancies with more results exceeding treatment of metastatic malignant melanoma eagerly awaited.
